AXGN Stock Overview
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.11|
|52 Week High||US$23.94|
|52 Week Low||US$9.11|
|1 Month Change||-33.66%|
|3 Month Change||-41.80%|
|1 Year Change||-36.25%|
|3 Year Change||-67.60%|
|5 Year Change||21.08%|
|Change since IPO||273.06%|
Recent News & Updates
Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing
Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels. COVID-19 infections are definitely a short-term risk and an impediment to sales and training efforts, but usage among trained surgeons and core accounts continues to grow nicely. Data in 2022 and 2023 should accelerate adoption, helping smooth the path to 20% or better revenue growth with products that provide demonstrable clinical and quality of life benefits. Axogen shares look undervalued below the mid-$20s.
Is AxoGen (NASDAQ:AXGN) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|AXGN||US Medical Equipment||US Market|
Return vs Industry: AXGN underperformed the US Medical Equipment industry which returned 9.5% over the past year.
Return vs Market: AXGN underperformed the US Market which returned 17.8% over the past year.
|AXGN Average Weekly Movement||8.4%|
|Medical Equipment Industry Average Movement||7.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: AXGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AXGN's weekly volatility (8%) has been stable over the past year.
About the Company
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed.
AxoGen Fundamentals Summary
|AXGN fundamental statistics|
Is AXGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AXGN income statement (TTM)|
|Cost of Revenue||US$22.97m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.67|
|Net Profit Margin||-21.59%|
How did AXGN perform over the long term?See historical performance and comparison
Is AxoGen undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AXGN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: AXGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AXGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AXGN's PB Ratio (3.6x) is in line with the US Medical Equipment industry average.
How is AxoGen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AXGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AXGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AXGN's revenue (17.6% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: AXGN's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AXGN's Return on Equity is forecast to be high in 3 years time
How has AxoGen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AXGN is currently unprofitable.
Growing Profit Margin: AXGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AXGN is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.
Accelerating Growth: Unable to compare AXGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).
Return on Equity
High ROE: AXGN has a negative Return on Equity (-24.04%), as it is currently unprofitable.
How is AxoGen's financial position?
Financial Position Analysis
Short Term Liabilities: AXGN's short term assets ($135.0M) exceed its short term liabilities ($23.4M).
Long Term Liabilities: AXGN's short term assets ($135.0M) exceed its long term liabilities ($71.3M).
Debt to Equity History and Analysis
Debt Level: AXGN has more cash than its total debt.
Reducing Debt: AXGN's debt to equity ratio has reduced from 1993% to 43.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AXGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AXGN has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 20.1% each year.
What is AxoGen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AXGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AXGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AXGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AXGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AXGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Karen Zaderej (59 yo)
Ms. Karen Zaderej has been President and Chief Executive Officer of AxoGen, Inc. since September 30, 2011. She was the Director of Viveve Medical Inc. from September 13, 2018 until May 4, 2020. She has ser...
CEO Compensation Analysis
Compensation vs Market: Karen's total compensation ($USD4.05M) is above average for companies of similar size in the US market ($USD1.75M).
Compensation vs Earnings: Karen's compensation has increased whilst the company is unprofitable.
Experienced Management: AXGN's management team is considered experienced (3.3 years average tenure).
Experienced Board: AXGN's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.
AxoGen, Inc.'s employee growth, exchange listings and data sources
- Name: AxoGen, Inc.
- Ticker: AXGN
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$391.935m
- Shares outstanding: 41.56m
- Website: https://www.axogeninc.com
Number of Employees
- AxoGen, Inc.
- 13631 Progress Boulevard
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 23:40|
|End of Day Share Price||2021/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.